Ann: Appendix 4C - quarterly, page-60

I agree. very frustrating as it seems this is a great alternative to gandolium as a contrast agent. The biggest problem here is getting participants to take part in the trial, but that is absolutely no reflection on the validity or effectiveness of the product once approved. It could be a huge shift in what is regarded as standard diagnosis technique.
Obviously the issue is trial participants need to be very specific sub group that have just received a life changing diagnosis already. Not sure how opening multiple centres will help though. Surely same issue at every centre. How do you incentivise someone to proceed with this trial?